

**NC Medicaid
Pharmacy Prior Approval Request
Immunomodulators: Xeljanz XR**

Beneficiary Information

1. Beneficiary Last Name: _____ 2. First Name: _____
3. Beneficiary ID #: _____ 4. Beneficiary Date of Birth: _____ 5. Beneficiary Gender: _____

Prescriber Information

6. Prescribing Provider NPI #: _____
7. Requester Contact Information - Name: _____ Phone #: _____ Ext. _____

Drug Information

8. Drug Name: _____ 9. Strength: _____ 10. Quantity Per 30 Days: _____
11. Length of Therapy (in days): up to 30 Days 60 Days 90 Days 120 Days 180 Days 365 Days
Other _____

Clinical Information

Request for Ankylosing Spondylitis

1. Does the beneficiary have a diagnosis of Ankylosing Spondylitis? Yes No
2. Is the beneficiary not on another injectable biologic immunomodulator? Yes No
3. Has the beneficiary individual risks and benefits been considered prior to initiating or continuing therapy in those at higher risk for malignancy and/or major adverse cardiovascular events (MACE)? Yes No
4. Is the beneficiary NOT considered to be at high risk for thrombosis? Yes No
5. Has the beneficiary been considered and screened for the presence of latent tuberculosis infection? Yes No
6. Has the beneficiary been tested with Hep B SAG and Core Ab? Yes No
7. Will the beneficiary NOT receive live vaccines during therapy? Yes No
8. Has the beneficiary tried at least one Tumor Necrosis Factor Blocker with inadequate response or unable to take these therapies due to intolerance or contraindications? Yes No
9. Has the beneficiary had a trial and failure of Cosentyx, Enbrel or Humira or a clinical reason beneficiary cannot try Cosentyx, Enbrel or Humira? Yes No

Request for Psoriatic Arthritis

1. Does the beneficiary have a documented definitive diagnosis of Psoriatic Arthritis? Yes No
2. Is the beneficiary 18 years of age or older? Yes No
3. Is the beneficiary not on another injectable biologic immunomodulator? Yes No
4. Has the beneficiary individual risks and benefits been considered prior to initiating or continuing therapy in those at higher risk for malignancy and/or major adverse cardiovascular events (MACE)? Yes No
5. Is the beneficiary NOT considered to be at high risk for thrombosis? Yes No
6. Has the beneficiary been considered and screened for the presence of latent tuberculosis infection? Yes No
7. Has the beneficiary been tested with Hep B SAG and Core Ab? Yes No
8. Does the beneficiary have a documented inadequate response, intolerance or contraindication to at least one Tumor Necrosis Factor Blocker? Yes No

**NC Medicaid
Pharmacy Prior Approval Request**

9. Has the beneficiary had a trial and failure of Cosentyx, Enbrel or Humira or a clinical reason beneficiary cannot try Cosentyx, Enbrel or Humira? Yes No

Request for Rheumatoid Arthritis

1. Does the beneficiary have a diagnosis of Rheumatoid Arthritis? Yes No
2. Is the beneficiary not on another injectable biologic immunomodulator? Yes No
3. Has the beneficiary individual risks and benefits been considered prior to initiating or continuing therapy in those at higher risk for malignancy and/or major adverse cardiovascular events (MACE)? Yes No
4. Is the beneficiary NOT considered to be at high risk for thrombosis? Yes No
5. Has the beneficiary been considered and screened for the presence of latent tuberculosis? Yes No
6. Has the beneficiary been tested with Hep B SAG and Core Ab? Yes No
7. Will the beneficiary NOT receive live vaccines during therapy? Yes No
8. Has the beneficiary experienced a therapeutic failure/inadequate response with at least one Tumor Necrosis Factor Blocker? Yes No
9. Is the beneficiary unable to receive Tumor Necrosis Factor Blocker due to contraindications or intolerabilities?
 Yes No
10. Has the beneficiary had a trial and failure of Enbrel or Humira or a clinical reason beneficiary cannot try Enbrel or Humira? Yes No

Request for Ulcerative Colitis (Adult)

1. Does the beneficiary have a diagnosis of ulcerative colitis? Yes No
2. Is the beneficiary not on another injectable biologic immunomodulator? Yes No
3. Has the beneficiary individual risks and benefits been considered prior to initiating or continuing therapy in those at higher risk for malignancy and/or major adverse cardiovascular events (MACE)? Yes No
4. Is the beneficiary NOT considered to be at high risk for thrombosis? Yes No
5. Has the beneficiary been considered and screened for the presence of latent tuberculosis? Yes No
6. Has the beneficiary been tested with Hep B SAG and Core Ab? Yes No
7. Will the beneficiary NOT receive live vaccines during therapy? Yes No
8. Has the beneficiary had a trial and failure of Humira or a clinical reason beneficiary cannot try Humira? Yes No

Signature of Prescriber: _____ Date: _____

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.